Trevor James
The RSV vaccine is currently recommended as a single dose for adults aged 75 and older and for those aged 50 to 74 with an increased risk of severe RSV. The CDC also recommends one dose of nirsevimab for all infants younger than 8 months. For now, only one dose of the RSV vaccine is recommended, and it is not an annual vaccine. However, the need for additional doses will be evaluated in the future.
| Characteristics | Values |
|---|---|
| Recommended age for vaccination | 50 years and older |
| Number of doses | 1 |
| Time between doses | N/A |
| Seasonal | Yes |
| Best time to get vaccinated | Late summer and early fall |
| Annual vaccine | No |
| Side effects | Pain, redness, and swelling at the injection site, fever, headache, myalgia, tiredness, aches, nausea, or diarrhea |
| Serious side effects | Guillain-Barré syndrome, serious inflammatory neurological events |
| Allergic reactions | Anaphylaxis |
| People at risk | People with chronic medical conditions such as lung diseases, cardiovascular diseases, neurologic or neuromuscular conditions, kidney disorders, liver disorders, diabetes, or moderate or severe immune compromise, older adults, infants |
Explore related products
What You'll Learn
The RSV vaccine is not an annual vaccine
The RSV vaccine is not currently an annual vaccine. According to the CDC, a single dose of the RSV vaccine is recommended for eligible adults, and this dose provides protection against RSV disease for at least two years. The best time to get the vaccine is in late summer or early fall before the RSV season starts, but it can be taken at any time.
RSV is a serious disease, especially for older adults, and can cause an infection of the lungs similar to the flu. It is highly contagious and can lead to life-threatening pneumonia. The RSV vaccine can help older adults at risk of RSV, and the CDC recommends that adults 75 years old or older should receive the vaccine. Adults 60-74 years old who are at increased risk of severe RSV should also receive the vaccine.
The RSV vaccine has been approved for use in adults with serious health conditions who are most at risk if they get RSV. These include people with chronic medical conditions such as lung diseases, cardiovascular diseases, neurologic or neuromuscular conditions, kidney disorders, liver disorders, diabetes, or moderate to severe immune compromise.
For infants, a medication called nirsevimab can be administered to those born during the RSV season. Nirsevimab is a single shot that provides protection for about five months. The CDC recommends one dose of nirsevimab for all infants younger than 8 months.
The RSV vaccine is not without its risks, however. A small number of people experienced serious inflammatory neurological events after receiving the vaccine. Other possible side effects include pain, redness, or swelling at the injection site, tiredness, body aches, fever, nausea, or diarrhea.
Vaccine Education: A Nurse's Guide to Patient Teaching
You may want to see also
Explore related products
$5 $32.99
One shot is a lifetime dose
The RSV vaccine is not currently an annual vaccine. The CDC recommends only a single dose of the RSV vaccine for all adults 75 and older and for adults 50-74 with an increased risk of severe RSV disease. The RSV vaccine was first approved in 2023, and if you've already gotten a single dose of an RSV vaccine, you don't need to worry about getting another dose now. "You should be good. At this point in time, a single shot is considered a lifetime dose, so you should not get another one," said Dr. Michelle Barron.
RSV can be serious for infants and older adults. When severe, it can lead to bronchiolitis or pneumonia. RSV outbreaks tend to occur from October to May each year. People with RSV do not develop natural immunity to it, so it's possible to get the virus multiple times a season. Symptoms of RSV can be similar to other viruses, like a cold or the flu, and may include a runny nose, sore throat, or cough. In many places, testing for the flu also involves testing for RSV. This is because the flu and RSV seasons typically overlap, and the viruses have similar symptoms.
The RSV vaccine can help older adults at risk of RSV. There are three different RSV vaccines used for adults 60 years old or older. The vaccines are made by Pfizer, GSK, and Moderna. The CDC recommends that adults 75 years old or older should receive the RSV vaccine. Adults 60-74 years old who are at increased risk for severe RSV should also receive the vaccine. Your healthcare professional will consider your risk factors for getting seriously sick from RSV when helping you decide whether to get the vaccine.
For infants, nirsevimab is a single shot that is long-lasting and can be given with other age-appropriate childhood vaccines. Studies have shown that protection from nirsevimab lasts for about five months. The CDC recommends one dose of nirsevimab for all infants younger than 8 months, born during—or entering—their first RSV season, which is typically fall through spring.
Vaccination Programs: 20th Century's Fight Against Diseases
You may want to see also
Explore related products
The best time to get the vaccine is in late summer or early fall
The RSV vaccine is not currently an annual vaccine, and eligible adults can get an RSV vaccine at any time. However, the best time to get vaccinated is in late summer or early fall, usually from August to October, before the RSV season usually starts. RSV season often starts in the fall and peaks in winter. Getting the vaccine in late summer or early fall can ensure that antibody levels are highest during the RSV season that follows.
The CDC recommends a single dose of RSV vaccine for certain adults to help prevent serious RSV infection and hospitalization. The RSV vaccine is given as a single dose, and CDC recommends an RSV vaccine for all adults ages 75 years and older and for adults ages 50–74 years who are at increased risk of severe RSV. The RSV vaccine works by causing an immune response that can protect you from respiratory disease if you get RSV in the future.
If you have a moderate or severe illness, you should wait until you recover before receiving an RSV vaccine. If you have a minor illness, such as a cold, you can get an RSV vaccine. One dose of RSV vaccine provides protection against RSV disease in adults ages 50 years and older for at least two years.
The typical RSV seasonality was disrupted by the COVID-19 pandemic and has not returned to pre-pandemic patterns yet. For physicians recommending RSV vaccination based on shared clinical decision-making, a vaccine should be administered as early as the supply becomes available, according to the CDC.
RSV and Pneumonia Vaccines: Are They the Same?
You may want to see also
Explore related products
The RSV vaccine is recommended for infants and older adults
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms, with most people recovering within one or two weeks. However, RSV is one of the most common causes of hospitalisation in infants and older adults, particularly those with chronic medical conditions. RSV season often starts in the fall and peaks in winter.
The CDC recommends one dose of nirsevimab for all infants younger than 8 months, born during or entering their first RSV season, which is typically fall through spring. Nirsevimab is a monoclonal antibody that prevents severe RSV disease and is recommended for infants and some young children. It is not a vaccine. Nirsevimab is highly effective in preventing RSV-associated hospitalisation. Side effects are usually mild, such as pain, redness, or swelling where the injection was given, and they resolve quickly.
For a small group of children between 8 and 19 months old who are at an increased risk of severe RSV disease—such as children who are severely immunocompromised—a dose is recommended in their second season. There is also a preventive medication available called palivizumab, marketed as Synagis. It is a monoclonal antibody that is given monthly to babies under 24 months old and is recommended only for infants with certain high-risk conditions.
Maternal RSV vaccination is also recommended to protect newborns from birth to 6 months of age. The vaccine is available from September to January to provide protection for newborns when infection rates are expected to be at their highest, between October and March.
The RSV vaccine is recommended for all adults 75 years and older and for adults 50–74 years old who are at an increased risk of severe RSV. Risk factors include chronic cardiovascular disease, chronic lung or respiratory disease, end-stage renal disease, and diabetes or moderate or severe immune compromise.
Vaccines Preventing STIs: What You Need to Know
You may want to see also
Explore related products
![International Certificate of Vaccination with Vinyl Document Holder - World Health Organization Bilingual Version [cards] World Health Organization [Jan 01, 2007]](https://m.media-amazon.com/images/I/61SHjBP1VYL._AC_UL320_.jpg)
RSV vaccines are relatively expensive
The RSV vaccine is a one-time shot, with a single dose providing protection against RSV disease for at least two years in adults aged 50 and older. However, it is not currently an annual vaccine, and those who have already received one dose do not need another. Clinical trial data for the Abrysvo vaccine showed protection for approximately 18 months following vaccination, with some waning over time. The vaccine's effectiveness is still being monitored, and it is possible that additional doses may be recommended in the future.
For those without insurance, there are still options to help make the vaccine more affordable. Patient assistance programs and discounts are often available to help lower the price of the vaccine. Additionally, GoodRx coupons can be used to receive a discount on the vaccine at certain pharmacies. Community health centers and pop-up vaccine clinics may also offer the vaccine at a lower cost through various public health initiatives.
The high cost of the RSV vaccine may be a barrier for some individuals, especially those without insurance or with high out-of-pocket costs. However, there are resources and initiatives in place to help make the vaccine more accessible to those who need it. It is important to note that the vaccine is recommended for adults over the age of 50 and those with certain underlying medical conditions, as they are at a higher risk of developing severe RSV.
Hepatitis B Vaccination: Why Am I Still at Risk?
You may want to see also
Frequently asked questions
Yes, the RSV vaccine is currently recommended as a single lifetime dose for adults. The CDC recommends a single dose of RSV vaccine for certain adults to help prevent serious RSV infection and hospitalization.
The CDC recommends the RSV vaccine for all adults aged 75 years and older. Adults aged 50-74 years with an increased risk of severe RSV should also receive the vaccine. For infants, a medication called nirsevimab is available to those who are born prematurely or during the RSV season.
The best time to get the RSV vaccine is in late summer and early fall before the RSV season. In most of the continental United States, this corresponds to vaccination during August-October.
